Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Abt P, Shaked A. 2003. The allograft immune response. Graft. 6:71–79.
Alegre ML, Najafian N. 2006. Costimulatory molecules as targets for the induction of transplantation tolerance. Curr Mol Med. 6:843–857.
Antin JH, Ferrara JL. 1992. Cytokine dysregulation and acute graft vs host disease. Blood. 80:2964–2968.
Arkelov A, Lakkis FG. 2000. The alloimmune response and effector mechanisms of allograft rejection. Semin Nephrol. 20:95–102.
Azuma H, Tilney NL. 1995. Immune and nonimmune mechanisms of chronic rejection of kidney allografts. J Heat Lung Transplant. 14:S136–S142.
Bellgrau D, Gold D, Selawry H, Moore J, et al. 1995. A role for CD95 ligand in preventing graft rejection. Nature. 377:630–632.
Benichou G, Fedoseyeva EV. 1996. The contribution of peptides to T cell allorecognition and allograft rejection. Int Rev Immunol. 13:231–243.
Benjamin LC, Allan JS, Madsen JC. 2002. Cytokines in immunity and allograft rejection. Crit Rev Immunol. 22:269–279.
Betkowski AS, Graff R, Chen JJ, Hauptman PJ. 2002. Panel- reactive antibody screening practices prior to heart transplantation. J Heart Lung Transplant. 21:644–650.
Billingham RE. 1966. The biology of graft-versus-host reactions. Harvey Lect. 67:21–78.
Bishop DK, Shelby J, Eichwald EJ. 1992. Mobilization of T lymphocytes following cardiac transplantation. Evidence that CD4- positive cells are required for cytotoxic T lymphocyte activation, inflammatory endothelial development, graft infiltration and acute allograft rejection. Transplantation. 53:849–857.
Bishop DK, Li W, Chan SY, Ensley RD, et al. 1994. Helper T lymphocytes unresponsiveness to cardiac allografts following transient depletion of CD4-positive cells. Implications for cellular and humoral responses. Transplantation. 58:576–584.
Brent L. 1997. History of Transplantation Immunology. Academic Press, San Diego, CA.
Broelsch CE, Burdelski M, Rogiers X, Gundlach M, et al. 1994. Living donor for liver transplantation. Hepatology. 20:49S–55S.
Bromberg JS, Murphy B. 2001. Routes to allograft survival. J Clin Inv. 107:797–798.
Brook NR, Nicholson ML. 2003. Kidney transplantation from non heart-beating donors. Surgeon. 1:311–322.
Bucin D. 1988. Blood transfusion in renal transplantation – The induction of tolerance by incompatibility for class I antigen. Med Hypothesis. 27:19–27.
Chalasani G, Li Q, Konieczny BT, Smith-Diggs L, et al. 2004. The allograft defines the type of rejection (acute vs chronic) in the face of an established effector immune response. J Immunol. 172:7813–7820.
Codarri L, Vallotton L, Ciuffreda D, Venetz JP, et al. 2007. Expansion and tissue infiltration of an allospecific CD4+CD25+CD45RO+IL-7R (alpha) high cell population in solid organ transplant recipients. J Exp Med. 204:1533–1541.
Cooper DK. 1969. Transplantation of the heart and both lungs. I. Historical review. Thorax. 24:383–390.
Doyle AM, Lechler RI, Turka LA. 2004. Organ transplantation: Half-way through the first century. J Am Soc Nephrol. 15:2965–2971.
Dreger P, Kloss M, Petersen B, Haferlach T, et al. 1995. -Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 86:3970–3978.
El-Asady RS, Rongwen Y, Hadley GA. 2003. The role of CD103 ([alpha]E[beta] 7 integrin) and other adhesion molecules in lymphocyte migration to organ allografts: Mechanisms of rejection. Curr Opin Organ Transplant. 8:1–6.
Ferrara JL, Deeg HJ. 1991. Graft-versus-host disease. NEJM. 324:667–674.
Ferrara JLM, Cooke KR, Pan L, Krenger W. 1996. The immunopathophysiology of acute graft-versus-host-disease. Stem cells. 14:473–489.
Field EH, Matesic D, Rigby S, Fehr T, et al. 2001. CD4+CD25+ regulatory cells in acquired MHC tolerance. Immunol Rev. 182:99–112.
Flye MW (Ed.). 1989. Principles of Organ Transplantation. W. B. Saunders, Philadelphia, PA.
Galili U. 1993. Interaction of the natural anti-Gal antibody with α-galactosyl epitopes: A major obstacle of xenotransplantation in humans. Immunol Today. 14:480–482.
Game DS, Lechler RI. 2002. Pathways of allorecognition: Implications for transplantation tolerance. Transpl Immunol. 10:101–108.
Gebel HM, Bray RA. 2000. Sensitization and sensitivity: Defining the unsensitized patients. Transplantation. 69:1370–1374.
Goulmy E, Schipper R, Pool J, Blokland E, et al. 1996. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host-disease after bone marrow transplantation. NEJM. 334:281–285.
Griepp RB, Ergin MA. 1984. The history of experimental heart transplantation. J Heart Transplant. 3:145–145.
Griffith BP, Hardesty RL, Trento A, Bahnson HT. 1985. Asynchronous rejection of heart and lungs following cardiopulmonary transplantation. Ann Thorac Surg. 40:488–493.
Griffith TS, Brunner T, Fletcher SM, Green DR, et al. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:11889–1192.
Hakim NS. 2003. Recent developments and future prospects in pancreatic transplantation. Exp Clin Transplant. 1:26–34.
Hall B, Jelbart ME, Gurley KE, Dorsch SE. 1990. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of CD4+ suppressor cell and its mechanisms of action. J Exp Med. 171:141–157.
Hall BM, Chen J, Robinson C, Xy H, et al. 2002. Therapy with mab to CD25 blocks function of CD4+CD25+ T regulatory cells which maintain transplantation tolerance. Nephrology. 7:A111–A111.
Hayry P, Isoniemi H, Yilmaz A, Mennander K, et al. 1993. Chronic allograft rejection. Immunol Rev. 134:33–81.
Hayry P. 1996. Pathophysiology of chronic rejection. Trans Proc. 28:7–10.
Kahan BD. 1991. Transplantation timeline. Mankind’s three millennia-one maverick’s three decades in the struggle against biochemical individuality. Transplantation. 51:1–21.
Kang SM, Tang Q, Bluestone JA. 2007. CD4+CD25+ regulatory T cells in transplantation: Progress, challenges and prospects. Am J Transplant. 7:1457–1463.
Kaufman DB, A. 2006. Pancreas transplantation. Koffron www.emedicine.com/med/topic 2605.htm.
Kerman RH, Orosz CG, Lorber MI. 1997. Clinical relevance of anti-HLA antibodies pre and post transplant. Am J Med Sci. 313:275–278.
Kitchens WH, Uehara S, Chase CM, Coluin RB, et al. 2006. The changing role of natural killer cells in solid organ rejection and tolerance. Transplantation. 81:811–817.
Klein J. 1986. Natural History of the Major Histocompatibility Complex. Wiley, New York.
Krensky AM. 2004. Immunologic tolerance. Ped Nephrol. 16:675–679.
Krensky AM, Clayberger C. 2004. Prospects for induction of tolerance in renal transplantation. Ped Nephrol. 8:772–779.
Krieger NR, Yin DP, Fathman CG. 1996. CD4+ but not CD8+ cells are essential for allorejection. J Exp Med. 184:2013–2018.
LaRosa DF, Rahman AH, Turka LA. 2007. The innate immune system in allograft rejection and tolerance. J Immunol. 178:7503–7509.
Lattmann T, Hein M, HOrber S, Ortmann J, et al. 2005. Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: Role of endothelin receptor signaling. Am J Transplant. 5:1042–1049.
Lau CL, Palmer SM, Posther KE, Howell DN, et al. 2000. Influence of panel-reactive antibodies on post transplant outcomes in lung transplant recipients. Ann Thorac Surg. 69:1520–1524.
Lau HT, Yu M, Fontana A, Stoeckert CJ. 1996. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science. 273:109–112.
Majno G. 1975. The Healing Hand. Man and Wound in the Ancient World. Harvard University Press, Cambridge, MA.
Mancini MC. 2006. Heart-lung transplantation. www.emedicine.com/med/topic2063.htm.
Mancini MC, Gangahar DM. 2006. Heart transplantation. www.emedicine.com/med/topic 3187.htm.
Mandanas RA. 2006. Graft vs. host disease. www.emedicine.com/medtopic926.htm.
Manzarbeitia C. 2006. Liver transplantation. www.emedicine.com/med/topic3510.htm.
Matthews LG. 1968. S.S. Cosmas and Damian – Patron Saints of medicine and pharmacy. Their cult in England. Med Hist. 12:281–288.
Medawar PB. 1986. Memoir of a Thinking Radish. Oxford University Press, Oxford.
Merrill JP, Murray JE, Harrison JH, Guild WR. 1984. Landmark article Jan. 28, 1956. Successful homotransplantation of the human kidney between identical twins. JAMA. 251:2566–2571.
Morris PJ. 2004. Transplantation – A medical miracle of the 20th century. NEJM. 351:2678–2680.
Murphy B, Krensky AM. 1999. HLA-derived peptides as novel immunomodulatory therapeutics. J Am Soc Nephrol. 10:1346–1355.
Norman DJ. 1998. Expected clinical outcomes/risk factors. In: Norman DJ, Suke WN, Thorofare NJ, Eds. Primer on Transplantation, Am. Soc. Transplant Physicians, Thorofare, NJ,pp. 245–250.
Paul LC. 1995. Immunobiology of chronic renal transplant rejection. Blood Purif. 13:206–218.
Petersdorf EW, HansenJA, Martin PJ, Woolfrey A, et al. 2001. Major-histocompatibility-complex class I alleles and antigens in hematopoietic cell transplantation. NEJM. 345:1794–1800.
Philip T, Gugliemli C, Hagenbeek A, Somers R, et al. 1995. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. NEJM. 333:1540–1545.
Pinderski LJ, Kirklin JK, McGiffin D, Brown R, et al. 2005. Multi-organ transplantation: Is there a protective effect against acute and chronic rejection? J Heart Lung Transplant. 24:1828–1833.
Prescilla RP, Mattoo TK. 2006. Immunology of transplant rejection. www.emedicine.com/ped/ topic2841.htm.
Rana RE, Arora BS. 2002. History of plastic surgery in India. J Postgrad Med. 48:76–78.
Reitz BA, Wallwork JL, Hunt SA, Pennock JL, et al. 1982. Heart-lunch transplantation: Successful therapy for patients with pulmonary vascular disease. NEJM. 306:557–564.
Rocha PN, Plumb TJ, Crowley SD, Coffman TM. 2003. Effector mechanisms in transplant rejection. Immunol Rev. 196:51–64.
Roopenian D, Choi EY, Brown A. 2002. The immunogenomics of minor histocompatibility antigens. Immunol Rev. 190:86–94.
Rosenberg AS, Singer A. 1992. Cellular basis of skin allograft rejection: An in vivo model of immune-mediated tissue destruction. Ann Rev Immunol. 10:333–358.
Rossini AA, Greiner DL, Mordes JP. 1999. Induction of immunologic tolerance for transplantation. Physiol Rev. 79:99–41.
Roush W. 1995. Xenotransplantation. New ways to avoid organ rejection and buoy hopes. Science. 270:234–235.
Rubinstein P. 2001. HLA matching for bone marrow transplantation – How much is enough? NEJM. 345:1842–1844.
Ruiz P, Sarwar S, Suterwala MS. 2006. Graft versus host disease. www.emedicinecom/ped/topic 893.htm.
Sablinski T, Sayegh MH, Hancock WW, Kut JP, et al. 1991. Differential role of CD4+ cells in the sensitization and effector phases of accelerated graft rejection. Transplantation. 51:226–231.
Sade RM. 2005. Transplantation at 100 years: Alexis Carrel, pioneer surgeon. Ann Thorac Surg. 80:2415–2418.
Sakaguchi S. 2006. Regulatory T cells: Meden again. Immunol Rev. 212:1–5.
Sakaguchi S, Ono M, Setoguchi R, Yagi H, et al. 2006. Foxp3+CD25+Cd4+ natural regulatory T cells in dominant self tolerance and autoimmune disease. Immunol Rev. 212:8–27.
Salvalaggio PRO, Camirand G, Ariyan CD, Deng S, et al. 2006. Antigen exposure during enhanced CTLA-4 expression promotes allograft tolerance in vivo. J Immunol. 176:2292–2298.
Sanfilippo F. 1998. Transplantation tolerance – The search continues. NEJM. 339:1700–1702.
Sayegh MH, Carpenter CB. 1996. Role of indirect allorecognition in allograft rejection. Int Rev Immunol. 13:221–229.
Sayegh MH, Turka LA. 1998. The role of T cell costimulatory activation pathways in transplant rejection. NEJM. 338:1813–1821.
Sayegh MH, Carpenter CB. 2004. Transplantation 50 years later – Progress, challenges and promises. NEJM. 351:2761–2766.
Scheinfeld NS, Kuechle MK. 2007. Graft versus host disease. www.emedicine.com/derm/ toic478.htm.
Shapiro AMJ, Lakey JRT, Ryan EA. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. NEJM. 343:230–238.
Sho M, Kishimoto K, Harada H, Livak M, et al. 2005. Requirements for induction and maintenance of peripheral tolerance in stringent allograft models. Proc Nat Acad Sci. 102:13230–13235.
Silverstein AM. 1988. A History of Immunology. Academic Press, San Diego, CA.
Socie G, Mary JY, Lemann M. 2004. Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression. Blood. 103:50–57.
Spierings E, Vermeulen CJ, Vogt MH, Doerner LE, et al. 2003. Identification of HLA class II restricted H-Y-specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched transplantation. Lancet. 362:610–615.
Strom TB. 2004. Is transplantation tolerable? J Clin Inv. 113:1681–1683.
Sullivan KM. 1999. Graft-versus-host disease. In: Thomas ED, Ed. Hematopoietic Cell Transplantation. 2 nd Ed. Blackwell Science, Boston, MA.
Sykes M. 1996. Immunobiology of transplantation. FASEB J. 10:721–730.
Tambur AR, Pamboukian SV, Costanzo MR, Herrera ND, et al. 2005. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation. 80:1019–1025.
Terasaki PE. (Ed.). 1991. A History of Transplantation: Thirty-Five Recollections. UCLA Tissue Typing Laboratory Press, Los Angeles, CA.
Thomas ED, Lochte HL Jr., Lu WC, Ferrebee JW. 1957. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. NEJM. 257:491–496.
Tilney NL. 2000. Transplantation and its biology: From fantasy to routine. J Appl Physiol. 89:1681–1689.
Valujskikh A, Lakkis FG. 2003. In remembrance of things past: Memory T cells and transplant rejection. Immunol Rev. 196:65–74.
Valujskikh A. 2006. The challenge of inhibiting alloreactive T-cell memory. Am J Transplant. 6:647–651.
Van Buskirk AM, Pidwell DJ, Adam PW, Orosz CG. 1997. Transplantation immunology. JAMA. 278:1993–1999.
Van Twuyver E, Mooijaart RJ, tenBerge IJ, Van der Horst AR, et al. 1991. Pretransplantation blood transfusion revisited. NEJM. 325:1210–1213.
Zhang Q, Chen Y, Fairchild RL, Heeger PS, et al. 2006. Lymphoid sequestration of alloreactive memory CD4 T cells promotes cardiac allograft survival. J Immunol. 176:770–777.
Zheng XX, Markees TG, Hancock WW, Li Y, et al. 1999. CTLA4 signals are required to optimally induce allograft tolerance with combined donor specific transfusion and anti-CD154 monoclonal antibody treatment. J Immunol. 162:4983–4990.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2008 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Khan, M.M. (2008). Tissue Transplantation. In: Immunopharmacology. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-77976-8_7
Download citation
DOI: https://doi.org/10.1007/978-0-387-77976-8_7
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-77975-1
Online ISBN: 978-0-387-77976-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)